AVD-104 Summary

Key Factors Driving AVD-104 Growth

1. Market Positioning and New Patient Opportunity

• AVD-104 is being positioned as a next-generation immunology therapy designed to address limitations of existing systemic treatments in chronic inflammatory diseases.
• The drug is intended for patients with inadequate response, loss of response, or tolerability issues with current biologics and small-molecule therapies.
• Rising prevalence of immune-mediated inflammatory diseases is expanding the addressable patient population.
• Differentiated scientific design and targeted immune modulation are driving early interest among specialists ahead of later-stage development.

2. Expansion Across Key Indications

• Inflammatory Bowel Disease: AVD-104 is being explored for ulcerative colitis and Crohn’s disease, where long-term disease control and safety remain key unmet needs.
• Other Autoimmune and Inflammatory Conditions: The mechanism of action supports potential applicability across additional immune-driven disorders.
• Biologic-Experienced Populations: Development strategy suggests positioning in patients who are refractory or intolerant to existing advanced therapies.
• Ongoing pipeline evaluation may enable future indication expansion, increasing long-term market reach.

 

3. Geographic Development Strategy

• AVD-104 is progressing through a globally oriented clinical development pathway, with initial focus on major regulatory markets.
• North America and Europe are expected to serve as primary development regions, supported by established Inflammatory Bowel Disease clinical trial infrastructure.
• Asia-Pacific markets represent longer-term growth opportunities due to rising disease prevalence and improving access to advanced immunology treatments.
• Strategic partnerships may support broader regional development and future commercialization.

 

4. Regulatory and Clinical Milestones

• AVD-104 remains in clinical-stage development, with regulatory engagement centered on defining appropriate efficacy and safety endpoints.
• Advancement into later-stage trials would significantly enhance the asset’s regulatory and commercial outlook.
• Potential future approvals in additional autoimmune indications could strengthen competitive positioning and diversify revenue potential.

 

5. Clinical Momentum in Core Inflammatory Indications

• Inflammatory Bowel Disease represents a major long-term growth driver, characterized by chronic treatment, high biologic usage, and ongoing therapy switching.
• AVD-104’s development reflects growing demand for durable efficacy with improved safety and tolerability.
• Increasing focus on early disease control and long-term outcomes supports adoption potential if clinical data are favorable.
• Positive clinical signals could position AVD-104 as a meaningful alternative within advanced therapy algorithms.

 

6. Competitive Differentiation and Market Trends

• AVD-104 is designed to deliver targeted immune modulation, potentially reducing systemic toxicity compared with conventional approaches.
• The therapy aligns with broader market trends favoring precision immunology, optimized benefit–risk profiles, and personalized treatment selection.
• Growing reliance on biomarker-guided therapy, real-world evidence, and value-based care models is expected to support future payer and prescriber confidence.
• If clinical differentiation is demonstrated, AVD-104 could secure a strong position in a competitive immunology landscape.

 

AVD-104 Recent Developments

Company communications have highlighted continued clinical advancement and pipeline prioritization for AVD-104, positioning it as an important investigational asset within the immunology portfolio. Updates have emphasized ongoing clinical evaluation, mechanism-driven differentiation, and strategic planning for future development milestones. While late-stage data have not yet been publicly disclosed, these announcements underscore sustained commitment to advancing AVD-104 toward broader clinical validation and regulatory engagement. 

 

“AVD-104 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of AVD-104 for potential indication like Dry age-related macular degeneration, Diabetic macular oedema, and Wet age-related macular degeneration in the 7MM. A detailed picture of AVD-104’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the AVD-104 for potential indications. The AVD-104 market report provides insights about AVD-104’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current AVD-104 performance, future market assessments inclusive of the AVD-104 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of AVD-104 sales forecasts, along with factors driving its market.

 

AVD-104 Drug Summary

AVD-104 is an investigational intravitreal glyco-immune therapeutic (GIT) nanoparticle developed by Aviceda Therapeutics for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal diseases. This sialic acid-coated, biodegradable nanoparticle targets self-pattern recognition receptors (Siglecs) on immune cells like macrophages and microglia, modulating the innate immune response by dampening pro-inflammatory cytokines while promoting resolution cytokines to restore retinal homeostasis and inhibit GA lesion growth. Phase II/III LUNA trial data show significant best-corrected visual acuity (BCVA) gains sustained at 3 months post-injection, safety with no drug-related serious adverse events or dose-limiting toxicities, and advancement to Phase III despite mixed topline results, positioning it as a potential functional vision-preserving therapy administered bimonthly. The report provides AVD-104’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

 

Scope of the AVD-104 Market Report

The report provides insights into:

• A comprehensive product overview including the AVD-104 MoA, description, dosage and administration, research and development activities in potential indication like Dry age-related macular degeneration, Diabetic macular oedema, and Wet age-related macular degeneration.
• Elaborated details on AVD-104 regulatory milestones and other development activities have been provided in AVD-104 market report.
• The report also highlights AVD-104‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The AVD-104 market report also covers the patents information, generic entry and impact on cost cut.
• The AVD-104 market report contains current and forecasted AVD-104 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The AVD-104 market report also features the SWOT analysis with analyst views for AVD-104 in potential indications.

 

Methodology

The AVD-104 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

AVD-104 Analytical Perspective by DelveInsight

In-depth AVD-104 Market Assessment

This AVD-104 sales market forecast report provides a detailed market assessment of AVD-104 for potential indication like Dry age-related macular degeneration, Diabetic macular oedema, and Wet age-related macular degeneration in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted AVD-104 sales data uptil 2034.

 

AVD-104 Clinical Assessment

The AVD-104 market report provides the clinical trials information of AVD-104 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

 

AVD-104 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

 

AVD-104 Market Potential & Revenue Forecast

• Projected market size for the AVD-104 and its key indications
• Estimated AVD-104 sales potential (AVD-104 peak sales forecasts)
• AVD-104 Pricing strategies and reimbursement landscape

 

AVD-104 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• AVD-104 Market positioning compared to existing treatments
• AVD-104 Strengths & weaknesses relative to competitors

 

AVD-104 Regulatory & Commercial Milestones

• AVD-104 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

 

AVD-104 Clinical Differentiation

• AVD-104 Efficacy & safety advantages over existing drugs
• AVD-104 Unique selling points

 

AVD-104 Market Report Highlights

• In the coming years, the AVD-104 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The AVD-104 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence AVD-104’s dominance.
• Other emerging products for corneal disorders are expected to give tough market competition to AVD-104 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of AVD-104 in potential indications.
• Analyse AVD-104 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted AVD-104 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of AVD-104 in potential indications.

 

Key Questions Answered In The AVD-104 Market Report

• What is the class of therapy, route of administration and mechanism of action of AVD-104? How strong is AVD-104’s clinical and commercial performance?
• What is AVD-104’s clinical trial status in each individual indications such as Dry age-related macular degeneration, Diabetic macular oedema, and Wet age-related macular degeneration and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AVD-104 Manufacturers?
• What are the key designations that have been granted to AVD-104 for potential indications? How are they going to impact AVD-104’s penetration in various geographies?
• What is the current and forecasted AVD-104 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of AVD-104 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 
• What are the other emerging products available and how are these giving competition to AVD-104 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is AVD-104? What is the duration of therapy and what are the geographical variations in cost per patient?